Reach Us +44-1522-440391
Aspirin Use And Risk Of Head And Neck Cancer: Evidence From The INHANCE Consortium | 32145
ISSN: 2161-1165

Epidemiology: Open Access
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Aspirin use and risk of head and neck cancer: Evidence from the INHANCE consortium

3rd International Conference on Epidemiology & Public Health

Tatiana V Macfarlane and Gary J Macfarlane

ScientificTracks Abstracts: Epidemiology (Sunnyvale)

DOI: 10.4172/2161-1165.S1.011


Background: Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) are widely used as analgesics and preventative
agents for vascular events. Few studies have investigated the role of NSAIDs specifically for head and neck cancer (HNC), and
the results are not consistent.
Aim: The aim of this study was to examine the effect of aspirin on the risk of HNC within the International Head and Neck
Cancer Epidemiology (INHANCE) Consortium (
Methods: Individual data were available from seven case-control studies conducted in ten countries (4372 cases and 7361
controls). Logistic regression with studies treated as random effects was used to estimate odds ratios (ORs) and 95% confidence
intervals (CIs) adjusted for age, gender, education, smoking, alcohol consumption and body mass index.
Results: Prevalence of regular aspirin use (at least once a week for year) varied between studies (2% - 57%), and majority of
participants (89%) used it for cardiovascular prevention. Regular aspirin use was associated with an overall risk reduction of
HNC (OR 0.80, 95% CI 0.76, 0.85). Analysis by duration showed further reduction with long term use (10 years or more OR
0.75, 95% CI 0.62, 0.90; test for trend P=0.006). We found an inverse association for all sub-sites (OR 0.81, 95% CI 0.65, 1.00
for oropharynx, OR 0.38, 95% CI 0.26, 0.55 for hypopharynx and 0.75 95% CI 0.67, 0.85 for larynx) except oral cavity (OR 1.04
95% CI 0.89, 1.21).
Conclusion: Aspirin use, particularly long-term, was associated with a decreased risk of HNC.


Tatiana V Macfarlane has completed her PhD in Epidemiology at the University of Manchester in England. She previously worked at the European Institute of
Oncology in Italy and International Agency for Research of Cancer in France. Her main research interests are in epidemiology of head and neck cancer and oral
health epidemiology. She has been involved in major international collaborations such as Alcohol-related Cancers and Genetic Susceptibility in Europe (ARCAGE)
and International Head and Neck Cancer Epidemiology Consortium (INHANCE). She has published over 120 peer reviewed papers.

Relevant Topics